journal cover

Immune checkpoints: A therapeutic target in triple negative breast cancer

Oncoimmunology

May 21, 2014

Akhil ChawlaElizabeth A Mittendorf

Abstract

Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% o...read more

Mentioned in this Paper

Monoclonal Antibodies
Monoclonal antibodies, antineoplastic
Diagnostic Radiology Modality
T-Lymphocyte
Non-Small Cell Lung Cancer Pathway
Triple Negative Breast Neoplasms
Non-Small Cell Lung Carcinoma
Melanoma vaccine
CD274 gene
MUROMONAB-CD3, Parenteral,5 MG Administered
3
47
Paper Details
References

Similar Papers Found In These Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute focuses on advancing cancer tratment through supporting clinical trials and translational research. Follow this feed to stay up to date on research from this institute.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.

Skin Cutaneous Melanoma

Cutaneous melanoma is a cancer of the pigment-producing cells known as melanocytes. While it has a 98 percent five-year survival rate when caught early, thousands of deaths are attributed to this cancer each year. Here is the latest research.

Hormone-Related Cancers

This feed focuses on hormone-related cancers including cancer of the breast, endometrium, ovary, prostate, testis, thyroid, and bone, all of which share unique mechanisms of carcinogenesis. Here is the latest research.

Kidney Carcinoma

Kidney or renal carcinoma is a malignant tumor that start in the kidney. Renal cell carcinoma and transitional cell carcinoma are the two most common types of kidney cancer. Several factors, both genetic and environmental, have been implicated in this cancer. Here is the latest research.

Renal Cell Carcinoma

Renal cell carcinoma, the most common type of kidney cancer, originates in the lining of the proximal convoluted tubule. Both genetic and lifestyle factors have been implicated with increased risk of developing this cancer. Here is the latest research on renal cell carcinoma.

© 2020 Meta ULC. All rights reserved

Immune checkpoints: A therapeutic target in triple negative breast cancer

Oncoimmunology

May 21, 2014

Akhil ChawlaElizabeth A Mittendorf

PMID: 24843833

DOI: 10.4161/onci.28325

Abstract

Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% o...read more

Mentioned in this Paper

Monoclonal Antibodies
Monoclonal antibodies, antineoplastic
Diagnostic Radiology Modality
T-Lymphocyte
Non-Small Cell Lung Cancer Pathway
Triple Negative Breast Neoplasms
Non-Small Cell Lung Carcinoma
Melanoma vaccine
CD274 gene
MUROMONAB-CD3, Parenteral,5 MG Administered
3
47

Similar Papers Found In These Feeds

Paper Details
References
/papers/immune-checkpoints-a-therapeutic-target-in-triple/24843833